Related Experiment Video
Updated: Jun 9, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data
Published on: October 23, 2020
Risk stratification in breast screening workshop
Andrew Anderson1, Cristina Visintin2, Antonis Antoniou3
1UK NSC secretariat, Sheffield/London, UK. Andrew.Anderson@dhsc.gov.uk.
Risk-stratified breast cancer (BC) screening aims to tailor screening intensity based on individual risk, potentially improving the balance of benefits and harms over current age-based programs. Further research is needed to refine models and infrastructure for effective implementation.
Area of Science:
- Oncology
- Public Health
- Biostatistics
Background:
- Current UK breast cancer (BC) screening targets women aged 50-71 to reduce mortality.
- High-risk women receive additional screening within the national program.
- Growing interest exists in personalizing screening through risk stratification.
Purpose of the Study:
- To evaluate risk stratification screening strategies for breast cancer.
- To inform the UK National Screening Committee (UK NSC) on potential benefits and harms.
- To identify evidence gaps for implementing risk-tailored screening.
Main Methods:
- Proceedings of a UK NSC workshop discussing risk prediction and decision-analytic models.
- Expert discussions on benefit-harm analysis and economic evaluations of risk-stratified programs.
- Review of current expert work and preliminary data.
Main Results:
- Experts discussed risk prediction and decision-analytic models for BC screening.
- Identified areas for further work include model comparison, risk assessment tools, digital infrastructure, acceptability, screening test choice, and reducing inequalities.
- A phased introduction with real-world evidence assessment is suggested for program-wide stratification.
Conclusions:
- Risk stratification offers a potential improvement over age-based breast cancer screening.
- Further research and careful planning are essential for successful implementation.
- Addressing identified gaps is crucial for developing effective, equitable risk-tailored screening programs.
More Related Videos
06:03Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis
Published on: February 6, 2020
11:34Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Cancer Survival Analysis